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Abstract 
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial 
morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, 
restaging, and treatment selection. Until recently, choline-based positron emission tomogra-
phy/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging 
technique for these purposes. However, its application is limited to patients with high PSA levels 
and Gleason scores. Prostate-specific membrane antigen (PSMA) is a promising new target for 
specific imaging of PCa, because it is upregulated in the majority of PCa. Moreover, PSMA can 
serve as a target for therapeutic applications. Currently, several small-molecule PSMA ligands with 
excellent in vivo tumor targeting characteristics are being investigated for their potential in 
theranostic applications in PCa. Here, a review of the recent developments in PSMA-based di-
agnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided. 
Key words: PSMA, prostate cancer, PET, radionuclide imaging, theranostics 
Introduction 
Prostate cancer (PCa) is the most common type 
of cancer in men worldwide leading to substantial 
morbidity and mortality. At present, imaging of PCa 
is indicated for primary diagnosis, staging and re-
staging, as well as for the detection of (biochemical) 
recurrent disease. Currently, conventional imaging 
modalities, including ultrasound, bone scintigraphy, 
and computed tomography (CT) are used to detect 
primary and metastatic PCa for staging and risk 
stratification. Despite significant efforts, conventional 
imaging of PCa does not contribute to patient man-
agement as much as imaging performed in patients 
with other common cancers. Magnetic resonance im-
aging (MRI), particularly innovative methods such as 
diffusion-weighted MRI (DWI), or dynamic con-
trast-enhanced MRI (DCE-MRI), which allow func-
tional assessment of the disease, are growingly im-
portant for imaging of PCa. However, these tech-
niques do not allow tumor-specific imaging. While 
radionuclide imaging techniques such as 
[18F]-fluorodeoxyglucose (FDG) positron emission 
tomography (PET)/CT provide high sensitivity to 
detect tumor lesions for numerous malignancies, this 
technique is inadequate for (re)staging of PCa, as a 
large fraction of PCa show limited [18F]-FDG uptake 
[1, 2].  
Choline radiolabeled with 11C or 18F represents a 
more suitable alternative to [18F]-FDG-PET/CT and is 
currently used in the clinics as PET tracer for 
(re)staging of PCa [3]. Choline is a key precursor in 
the biosynthesis of phosphatidylcholine, a major 
component of the cell membrane. Increased levels of 
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total choline incorporation have been observed in 
several malignancies [4, 5]. While choline-based 
PET/CT can be used in PCa patients in particular 
settings, such as for the evaluation of high-risk pa-
tients with high PSA levels and Gleason scores, this 
method has limited sensitivity for initial staging of 
patients, lymph node detection, as well as for restag-
ing of patients with biochemical recurrence with PSA 
< 2 ng/ml [6-10]. Due to the lack of sensitive imaging 
methods for PCa, extensive research is focused on the 
development of new tracers that allow more sensitive 
and specific detection of PCa lesions with PET [11]. 
The prostate-specific membrane antigen (PSMA) 
is a type II integral membrane glycoprotein that was 
first detected on the human prostatic carcinoma cell 
line LNCaP [12]. PSMA was identified as a homo-
logue of the protein N-acetyl-L-aspartyl-L-glutamate 
peptidase I (NAALADase I or folate hydrolase I), a 
protein which is active in the central nervous system, 
where it cleaves the neurotransmitter N-Acetyl-l- 
aspartyl-l-glutamate (NAAG) into N-acetylaspartate 
(NAA) and glutamate [13, 14]. In malignant tissue, 
PSMA has been suggested to be involved in angio-
genesis, as increased PSMA expression was found to 
be expressed in the stroma adjacent to neovasculature 
of solid tumors [15]. Due to its selective overexpres-
sion in 90-100% of local PCa lesions, as well as in 
cancerous lymph nodes, and bone metastases [16-18], 
PSMA is a reliable tissue marker for PCa and is con-
sidered an ideal target for theranostic applications [14, 
19-22].  
Increased PSMA expression is correlated with an 
increase in tumor grade, pathological stage, aneu-
ploidy, and biochemical recurrence. Most important-
ly, PSMA expression is upregulated when tumors 
become androgen-independent, showing upregulated 
PSMA expression after anti-androgen therapy in up to 
100% of the cases [23]. This characteristic makes 
PSMA particularly valuable, since it has potential as 
an early indicator of tumor progression after andro-
gen-deprivation therapy. PSMA expression was 
proven to be a prognostic factor for disease recurrence 
[24].  
One of the first imaging probes specifically tar-
geting PSMA was 111In-capromab pendetide (Pros-
tascint®), a 111In-labeled anti-PSMA antibody [25]. An 
important limitation of capromab pendetide is the fact 
that it binds to an intracellular domain of PSMA. 
Therefore, capromab pendetide either binds to viable 
tumor cells following internalization or to dying cells 
with disrupted cellular membranes. Because of the 
high non-specific uptake and the relatively poor tu-
mor-to-background ratios, the application of 
111In-capromab pendetide for imaging prostatic ma-
lignancies remained rather limited [26, 27]. 
Subsequently, high affinity antibodies directed 
against extracellular epitopes of PSMA have been 
developed, such as J415, J533, and J591 [28]. It was 
shown that 111In-J591 accurately targets bone and soft 
tissue metastatic PCa lesions [29] and that 
177Lu-labeled J591 can be used safely in radioim-
munotherapy (RIT) directed against micrometastatic 
PCa [30]. Major disadvantages limiting the use of ra-
diolabeled monoclonal antibodies as theranostic ra-
diopharmaceuticals are their relatively long circula-
tory half-life (3-4 days), poor tumor penetration, and 
low tumor-to-normal tissue ratios, especially at early 
time points. Small molecules, in contrast, exhibit rapid 
extravasation, rapid diffusion in the extravascular 
space, and faster blood clearance. This could result in 
high tumor-normal tissue contrast early after injection 
of the tracer.  
In search for PSMA tracers with such favorable 
characteristics, modified forms of NAALAdase inhib-
itors, which were originally developed for possible 
neuroprotective effects in neurological disorders such 
as ALS [31], have been evaluated for their potential to 
diagnose and treat PCa. A series of preclinical studies 
evaluated the role of radiolabeled small-molecule 
PSMA inhibiting ligands for imaging of human PCa 
using various radionuclides such as 11C [32], 18F [33], 
123I [34], 99mTc [34-36], and 68Ga [37, 38]. The com-
pounds used in these studies can be classified into 
three groups: (1) the urea-based compounds, (2) the 
glutamate phosphoramidates and (3) the 
2-(phosphinylmethyl) pentanedioic acids [21] (figure 
1). Overall, the PSMA ligands tested in these preclin-
ical studies showed high tumor uptake peaking at 0.5 
– 1 h in mice with PSMA-expressing tumors. At earlier 
time points, the contrast was impaired due to high 
blood levels. For imaging purposes, this time frame 
matches best with radionuclides with half-lives of 1-2 
h (i.e. 68Ga or 18F). In some of these preclinical studies, 
remarkable changes in affinity and tumor uptake 
were observed upon changes in the radiolabel, chela-
tor, and linker. First of all, it has been suggested that a 
spacer is required between the PSMA binding motif 
and the chelator. Chen et al. have compared PSMA 
ligands with different linker lengths and showed that 
an increased linker length enhanced the affinity for 
PSMA and increased tumor uptake [39]. The binding 
site for the glutamate-urea-lysine sequence is linked 
to a tunnel-like region (~20 Å) and by using a long 
linker, bulky chelated metals are situated outside the 
active site and will not interfere with binding to the 
active site of PSMA [39, 40]. Second, Huang et al. 
showed that strategic placement of (multiple) nega-
tive charges in the linker region significantly reduced 
the retention in non-target tissue, without reducing 
the accumulation in the tumor [41]. Finally, the in-
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troduction of hydrophobic naphtyl groups signifi-
cantly increased tumor uptake, while the retention in 
the kidney was reduced [42]. Based on these preclin-
ical aspects, several clinical studies evaluating PSMA 
ligands have been performed. In this review, the clin-
ical status on PSMA ligands for theranostic applica-
tions in PCa will be discussed.  
Diagnostic Imaging Using Radiolabeled 
PSMA Ligands in Prostate Cancer  
Since 2012, the number of clinical studies using 
urea-based PSMA ligands, such as 123/124/131I- 
MIP-1072/-1095 [43], 99mTc-MIP-1404/-1405 [44], 
68Ga-HBED-PSMA, [18F]-DCFBC [45], and 
[18F]-DCFPyl, exponentially increased [43, 45-49] 
(figure 2). Among these agents, the 68Ga- and 
18F-labeled compounds have attracted the most atten-
tion, as these compounds can be used for PET/CT 
imaging. However, the availability of 123I or 99mTc al-
lows SPECT/CT imaging in centers without facilities 
for PET. An overview on clinical studies using radio-
labeled PSMA ligands for PCa diagnosis is provided 
in table 1.  
 
 
 
Figure 1: Classification of small molecule PSMA inhibitors used in (pre-)clinical studies for PCa. 1: urea-based glutamate heterodimers, 2: phospho-
ramidates, 3: 2-(phosphinylmethyl) pentanedioic acids 
 
 
 
Figure 2: Small-molecule PSMA ligands currently being investigated for PCa imaging in clinical settings. All possess the characteristic glu-urea-lys core. 
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Table 1: Overview on diagnostic clinical studies using radiolabeled PSMA ligands for PCa diagnosis and therapy. 
PSMA ligand Study Year Ra-
dio-nuc
lide 
Patient 
no 
 GSC Medi-
an PSA  
Level 
(ng/ml) 
Admin-
istered 
dose 
(MBq) 
Scanning 
time points 
Organs that received the 
highest dose 
MIP-1072, 
MIP-1095 
Barrett et al.  2013 I-123 7 not pro-
vided 
121 
(mean) 
370 
(mean) 
4 h and 24 h 
p.i. 
(SPECT/CT) 
123I-MIP-1072: 
salivary glands: 0.058 urinary 
bladder wall: 0.092  
kidneys: 0.054 
123I-MIP-1095: 
the salivary glands: 0.160 
kidneys: 0.110 
thyroid: 0.100  
(mGy/MBq) 
MIP-1095 Zechmann et al.  2014 I-124/  
I-131 
16 7  
(median) 
110.5 67.4 
(mean) 
1, 4, 24, 48, 72 
h p.i. 
(PET/CT) 
salivary glands: 3.76 ± 2.29 
liver: 1.66 ± 0.61 
kidneys: 1.39 ± 0.56 
(mSv/MBq) 
MIP-1404 
MIP-1405 
Vallabhajosula et 
al. 
2014 Tc-99m 6 not pro-
vided 
15.8 
(mean) 
740 ± 
111 MBq 
3-5 h p.i. 
(SPECT/CT) 
99mTc-MIP-1404: 
kidneys: 0.0733 
salivary glands: 0.0524 
spleen: 0.0218 
99mTc-MIP-1405: 
urinary bladder wall: 0.0434 
kidneys: 0.0363 
salivary glands: 0.0301 
(mGy/MBq) 
Glu-NH-CO-N
H-Lys(Ahx)-HB
ED-CC 
Afshar-Oromieh 
et al. 
2013 Ga-68 37 7 
(median) 
3.3 121 
(median) 
1 and 3 h p.i. 
(PET/CT) 
intense tracer uptake: 
kidneys and salivary glands, 
moderate tracer uptake: 
lacrimal glands, liver, spleen 
and in small and large bowel 
(based on SUVmean and SU-
Vmax) 
Glu-NH-CO-N
H-Lys(Ahx)-HB
ED-CC 
Afshar-Oromieh 
et al. 
2014 Ga-68 20 7.6 
(mean) 
2.62 149 
(median) 
1 h p.i. 
(PET/CT) 
3 h p.i. 
(PET/MRI) 
 
Glu-NH-CO-N
H-Lys(Ahx)-HB
ED-CC 
Afshar-Oromieh 
et al. 
2014 Ga-68 37 7.4 
(mean) 
11.1 132 
(median) 
1 h p.i. 
(PET/CT) 
 
Glu-NH-CO-N
H-Lys(Ahx)-HB
ED-CC 
Afshar-Oromieh 
et al. 
2015 Ga-68 319 7.5 
(mean) 
161 154 
(median) 
45-75 min. p.i. 
(PET/CT) 
 
Glu-NH-CO-N
H-Lys(Ahx)-HB
ED-CC 
Eiber et al. 2015 Ga-68 248 7 
(median) 
1.99 155.5 
(mean) 
47-61 min. p.i. 
(PET/CT) 
 
DCFBC Cho et al.  2012 F-18 5 8.2 
(mean) 
10.5 370 
(mean) 
2 h p.i. 
(PET/CT) 
urinary bladder wall: 0.0324 
stomach: 0.0302  
heart wall: 0.0292  
kidneys: 0.0284 
(mGy/MBq) 
DCFPyl Szabo et al2 2015 F-18 9 8.2 
(mean) 
30.6 320.6 
(mean) 
2 h p.i. 
(PET/CT) 
kidneys: 0.0945  
urinary bladder wall: 0.0864  
submandibular glands: 0.0387 
(mGy/MBq) 
 
 
SPECT/CT imaging with I-123/I-124-labeled 
PSMA ligands 
Barrett et al. reported the first in man study with 
the two radioiodinated glutamate-urea-lysine PSMA 
inhibitors 123I-MIP-1072 [(S)-2-(3-((S)-1-carboxy-5-(4- 
iodobenzylamino)pentyl)ureido) pentanedioic acid] 
and 123I-MIP-1095 [(S)-2-(3-((S)-1-carboxy-5-(3-(4- 
iodophenyl)ureido)pentyl)ureido) pentanedioic acid] 
in patients with PCa [43]. 123I-MIP-1072 cleared from 
the body more rapidly than 123I-MIP-1095: 28% of 
123I-MIP-1072 versus 2% of 123I-MIP-1095 cleared 
within the first 6 hours. The effect has been attributed 
to the higher lipophilicity of 123I-MIP-1095 [43]. The 
estimated effective dose was 0.022 mSv/MBq and 
0.032 mSv/MBq for 123I-MIP-1072 and 123I-MIP-1095, 
respectively. In animals models, the tumor uptake of 
MIP-1095 was higher compared with MIP-1072, 
which was attributed to the 5-fold higher affinity of 
MIP-1095 over MIP-1072 (Kd = 0.81 ± 0.39 and 3.8 ± 1.3 
nM, respectively). This might be a result of additional 
hydrophobic interactions of the tracer with sites out-
side of the PSMA binding pocket [50]. For 
123I-MIP-1072, the organs receiving the highest radia-
tion dose were the salivary glands (0.058 mGy/MBq), 
urinary bladder wall (0.092 mGy/MBq) and kidneys 
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(0.054 mGy/MBq), while for 123I-MIP-1095, these were 
the salivary glands (0.160 mGy/MBq), kidneys (0.110 
mGy/MBq) and thyroid (0.100 mGy/MBq). The up-
take in the kidneys and the salivary glands is receptor 
mediated, as these organs express significant levels of 
PSMA [22]. In six patients with metastatic PCa, lesions 
visible with SPECT/CT imaging correlated with the 
radiologic evidence of metastatic disease. This study 
demonstrated that 123I-MIP-1072 and 123I-MIP-1095 
SPECT/CT are suitable tracers for detection of tumor 
lesions in the prostate gland, lymph nodes, and bones.  
SPECT/CT imaging with Tc-99m-labeled 
PSMA ligands 
Because 99mTc is the preferred radionuclide for 
developing SPECT radiopharmaceuticals, 2 
high-affinity small-molecule PSMA inhibitors derived 
from glutamate-urea-glutamate or gluta-
mate-urea-lysine pharmacophores, MIP-1404 and 
MIP-1405, chelated with single-amino-acid chelators 
(SAAC), were developed, which can be labeled with 
99mTc based on tricarbonyl chemistry [36]. The SAACs 
allow facile labeling with 99mTc at room temperature, 
have robust complex stability, and were designed to 
minimize hepatobiliary uptake [51]. Preclinical stud-
ies showed high tumor uptake and tumor-to-blood 
ratios early after injection of 99mTc-MIP-1404 and 
99mTc-MIP-1405. Vallabhajosula and colleagues eval-
uated the role of these tracers for detection of PCa 
lesions in 6 patients with radiographic evidence of 
metastatic disease [44]. Both 99mTc-MIP-1404 and 
99mTc-MIP-1405 cleared rapidly from the circulation, 
with 99mTc-MIP-1404 demonstrating significantly 
lower urinary activity (7%) than 99mTc-MIP-1405 
(26%). Both agents showed persistent uptake in the 
salivary, lacrimal, and parotid glands and rapid lo-
calization in bone and lymph node lesions as early as 
1 h p.i.. Tracer uptake in salivary and lacrimal glands 
most likely is due to PSMA expression within these 
tissues [14, 48, 52]. SPECT images with excellent tu-
mor-to-background contrast were obtained: tu-
mor-to-background ratios ranging from 3:1 at 4 h p.i. 
to 9:1 at 20 h p.i.. More tumor lesions were visualized 
with 99mTc-MIP-1404 and 99mTc-MIP-1405 than with 
conventional bone scans. Overall, this study shows 
that PSMA ligands are feasible for 99mTc-SPECT/CT 
based detection of PCa lesions. 
PET/CT imaging with Ga-68-labeled PSMA 
ligands 
During the past few years, the application 
of 68Ga-labeled peptides has attracted considerable 
interest for cancer imaging due to the physical char-
acteristics of 68Ga (t½=68 min, β+ = 1899 keV) [53] and 
the availability of reliable GMP-compliant 68Ge/68Ga 
generators. Moreover, the half-life of 68Ga matches the 
pharmacokinetics of the small PSMA inhibiting pep-
tides.  
One of the first PSMA inhibitors available for 
labeling with 68Ga and PET imaging of PCa were 
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA)-conjugated urea-based PSMA inhibitors, 
developed and tested preclinically by Banerjee et al. 
[37]. In their animal study, PSMA-specific tumor im-
aging, with moderate tumor uptake (3.29 ± 0.77% 
ID/g) and high tumor-to-blood (22:1) ratios at 2 h p.i., 
was obtained in PSMA-expressing tumors (Ki 1.2 nM). 
Tumor uptake in PSMA-negative tumors was only 
0.18 ± 0.03% ID/g at 2 h p.i.. Eder et al. prepared the 
68Ga-labeled PSMA inhibitor Glu-NH-CO-NH- 
Lys(Ahx)-HBED-CC using the chelator 
N,N’-bis[2–hydroxy-5-(carboxyethyl)-benzyl]ethylene
diamineN,N’-diacetic acid (HBED-CC). Potentially, 
HBED is a more attractive chelator for 68Ga than 
DOTA as it forms a more thermodynamically stable 
complex with 68Ga, even at room temperature [54]. 
Eder et al. compared Glu-NH-CO-NHLys(Ahx)- 
HBED-CC (Ki 12.0 ± 2.8 nM) to 
Glu-NH-CO-NH-Lys-DOTA (Ki 37.6 ± 14.3 nM) and 
demonstrated that the HBED-CC conjugated com-
pound had more favorable properties for PCa imag-
ing than the DOTA analogue [55]. 68Ga-labeled 
Glu-NH-CO-NH-Lys(Ahx)-HBED-CC showed fast 
blood clearance, relatively low liver uptake, and high 
specific uptake in PSMA-expressing tissues and tu-
mor (tumor uptake 7.7 ± 1.5% ID/g for the 
HBED-CC-conjugate, which was 2.6-fold higher 
compared to the DOTA compound). In addition, liver 
uptake of the HBED-CC conjugated ligand was 
5.7-fold lower.  
Based on the promising preclinical results, Af-
shar-Oromieh et al. investigated the role of the 
68Ga-labeled PSMA ligand Glu-NH-CO-NH- 
Lys(Ahx)-HBED-CC (68Ga-HBED-CC-PSMA) in a 
cohort of 37 patients (median PSA: 3.3 ng/ml, range: 
0.01-148 ng/ml, median GSC: 7.0) [48]. Patients re-
ceived 121.0 MBq (range 52 – 212 MBq) of 
68Ga-HBED-CC-PSMA. In 84% of the patients, PCa 
lesions were identified. PCa lesions were found in 
60% of the patients with PSA levels <2.2 ng/ml, while 
at PSA levels of >2.2 ng/ml, PCa lesions were found 
in all patients. Thus even at relatively low blood PSA 
levels, 68Ga-HBED-CC-PSMA-PET/CT identified le-
sions with high tumor-to-background ratios [48]. In 
vivo, tumor uptake of 68Ga-HBED-CC-PSMA was 
stable between 1 h and 3 h, while in normal tissue 
uptake slightly decreased between 1 and 3 h. As a 
result, late scans exhibited higher tu-
mor-to-background ratios, which might be useful 
when lesions remain unclear in an early scan. Besides 
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tumor uptake, high tracer uptake was observed in 
kidneys, salivary glands, spleen and liver [48]. An 
example of a PET/CT image of a patient with recur-
rent PCa who underwent 68Ga-HBED-CC-PSMA 
PET/CT (1 h p.i.) is presented in figure 3. 
In a subsequent study, 68Ga-HBED-CC-PSMA 
PET/CT (150 MBq) was compared with 
68Ga-HBED-CC-PSMA PET/MRI to evaluate whether 
PET/MRI could have additional value in the detec-
tion of PCa lesions [49]. Twenty patients (median 
PSA: 2.62 ng/ml, range: 0.51-73.60) were scanned 
with PET/CT 1 h p.i. and PET/MRI 3 h p.i.. Out of the 
75 lesions which were characterized further, four le-
sions unclear in PET/CT could be established being 
PCa lesions in PET/MRI. Pathological lesions visible 
on PET often correlated with signals on MRI, offering 
a considerable advantage for PET/MR imaging. 
Overall, PCa was detected more easily and more ac-
curately with 68Ga-HBED-CC-PSMA PET/MRI than 
with PET/CT. In figure 4, PET/CT and PET/MRI 
images of one patient are displayed, demonstrating 
that a suspect lymph node could be detected with 
68Ga-HBED-CC-PSMA PET/MRI but did not show 
increased PSMA ligand uptake in PET/CT. A poten-
tial disadvantage of PET/MRI imaging was the ap-
pearance of halo artefacts around the bladder and 
kidneys, resulting in a reduced PET signal, and po-
tentially making lesions in their vicinity undetectable 
(figure 5) [49]. 
As until recently, choline based PET/CT was the 
leading radionuclide imaging method for detec-
tion/staging of PCa, Afshar-Oromieh et al. directly 
compared 68Ga-HBED-CC-PSMA PET/CT with 
[18F]-Fluoromethylcholine (FCH) PET/CT to evaluate 
which technique is superior in the detection of PCa 
lesions [47]. In a restaging setting, 37 patients (mean 
PSA: 11.1 ng/ml, range: 0.01-116 ng/ml, mean GSC: 
7.4) were scanned with PET/CT at 1 h p.i.. At least 
one PCa lesion was detected with 
68Ga-HBED-CC-PSMA-PET/CT in 87% of the pa-
tients, whereas this was the case in only 70% of the 
patients when [18F]-FCH was used as a tracer. At PSA 
values >2.82 ng/ml, 68Ga-HBED-CC-PSMA could 
detect at least one lesion in each patient, for choline 
this was the case in 91% of the patients. At PSA levels 
<2.82 ng/ml at least one lesion could be detect in 69% 
and 44% of the patients using 68Ga-HBED-CC-PSMA 
and [18F]-FCH, respectively. Most importantly, all 
lesions visible in [18F]-FCH-PET/CT were also visible 
using 68Ga-HBED-CC-PSMA-PET/CT. Among the 78 
lesions identified using 68Ga-HBED-CC-PSMA- 
PET/CT, 40 were defined as lymph node metastases, 
23 as bone metastases, 10 as local relapses, and 5 as 
soft tissue metastases. The maximum standardized 
uptake values (SUVmax) were clearly (>10%) higher in 
68Ga-HBED-CC-PSMA-PET/CT compared to 
[18F]-FCH-PET/CT in 62 of 78 lesions, lower in 12 and 
equal in 4.  
 
 
Figure 3: 68Ga-HBED-CC-PSMA PET/CT image of a patient with locally recurrent PCa (PSA 3.7 ng/ml) after radical prostatectomy (SUVmax 12.4) who 
received 140 MBq of the 68Ga-labeled tracer molecule and was scanned at 1 h p.i.; a) CT image, b) PET image, c) PET/CT fusion image, d) MIP. 
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Figure 4: 68Ga-HBED-CC-PSMA PET/CT (a, b) and PET/MRI (c, d) images of a patient with PCa with recurrent disease in an inguinal lymph node (PSA 0.9 
ng/ml) after radical prostatectomy, scanned at 1 h and 3 h p.i., using PET/CT and PET/MRI, respectively. a) CT image, b) PET/CT fusion image, c) MR image 
(T2-weighted with contrast medium and turbo spin echo), d) PET/MRI fusion image. A metastatic lymph node is visible in the PET/MRI fusion image (green 
arrow), while the same lesion could not be visualized with PET/CT. 
 
Figure 5: 68Ga-HBED-CC-PSMA PET images of a patient with PCa after 
radical prostatectomy with recurrent disease in an inguinal lymph node. 
While the scatter corrected PET image from the PET/CT system (a) and 
the not scatter corrected PET image from the PET/MRI system (b) show no 
artefact, the scatter corrected PET image from the PET/MRI system shows 
an extensively reduced signal around the urinary bladder (b), previously 
described as ‘halo’ artefact [49]. 
Tumor-to-background ratios obtained with 
68Ga-HBED-CC-PSMA were higher in 74 out of 78 
lesions. In seven patients, these lesions were con-
firmed to be PCa by biopsy or surgery. No 
false-positives were found. Overall, this study sug-
gests a significantly improved sensitivity of 
68Ga-HBED-CC-PSMA-PET/CT compared with 
[18F]-FCH-PET/CT, especially at low PSA (<2.2 
ng/ml) [47]. In a similar study, Morigi et al. compared 
the tumor lesion detection rate of that of 
[18F]-FCH-PET/CT to that of 68Ga-HBED-CC- 
PSMA-PET/CT in 38 patients with biochemically re-
current PCa [56]. Of the 26 patients that had a positive 
scan, 54 % (14/26) were positive on PSMA alone, 42% 
(11/26) on both FCH and PSMA and only 4 % (1/26) 
on FCH alone. At PSA levels of <0.5ng/ml, PSMA 
detection rate was 50 % vs. 12.5% for FCH. At serum 
PSA levels between 0.5-2.0 ng/ml, the detection rate 
was 69 % for PSMA and 31 % for FCH, and at PSA 
>2.0, the detection rate was 86 % for PSMA and 57 % 
for FCH. It was shown that PSMA detected more le-
sions than FCH (59 and 29, respectively). Overall, 
these studies suggest that 68Ga-HBED-CC-PSMA- 
PET/CT is superior in the tumor lesion detection as 
compared to [18F]-FCH-PET/CT. 
 After proof-of-principle was provided that 
68Ga-HBED-CC-PSMA-PET/CT is feasible for the de-
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tection of PCa lesions, Afshar-Oromieh et al. retro-
spectively investigated the diagnostic value of 
68Ga-HBED-CC-PSMA-PET/CT in a larger group of 
patients (n=319) with PCa [57]. 68Ga-HBED-CC-PSMA 
PET/CT at 1 h p.i. detected PCa in 83% of the patients 
suspected recurrent PCa (264 of 319 patients). In ad-
dition, the tracer is highly specific for PCa: histologi-
cal analysis demonstrated that tracer accumulation in 
tumor lesions correlated with manifestations of PCa 
in virtually all cases without false-positive lesions. 
Eiber et al. reported the diagnostic accuracy of 
68Ga-HBED-CC-PSMA-PET/CT in 248 patients with 
biochemical recurrence after radical prostatectomy. In 
this study, 222 patients (89.5%) showed pathological 
findings in 68Ga-HBED-CC-PSMA-PET/CT, which 
implies a false-negative rate of 10.5% for 
68Ga-HBED-CC-PSMA-PET/CT imaging as in the 
case of biochemical recurrence by definition recurring 
tumor must be present. The detection rates were 
96.8%, 93%, 72.7%, and 57.9% in patients with serum 
PSA-levels of ≥2.1, <2.0 – 1.0, <1.0 - 0.5, and <0.5 - 0.2 
ng/ml, respectively. 68Ga-HBED-CC-PSMA-PET/CT 
showed substantially higher detection rates compared 
to reports in the literature stating detection rates be-
tween 34% and 88% for 11C-Choline, 43-79% for 
18F-Choline and 59-80% for 11C-Acetate [58, 59]. Most 
importantly, a high number of positive findings 
(11/19, 57.9%) in the clinically important range of low 
PSA-values (<0.5 ng/ml) was identified [58]. While it 
has been shown that the diagnostic value of 
68Ga-HBED-CC-PSMA-PET/CT in patients with PCa 
is relatively high, even in patients with low PSA se-
rum levels and compared to other tracers such as 
[18F]-FCH, approximately 40% of the patients with 
PSA levels of <0.5 ng/ml showed false-negative 
68Ga-HBED-CC-PSMA-PET/CT results [57]. There-
fore, Ceci et al. evaluated, which factors are associated 
with the 68Ga-HBED-CC-PSMA-PET/CT tumor lesion 
detection rate [60]. In this study, 70 patients with re-
current PCa which underwent 68Ga-HBED-CC- 
PSMA-PET/CT and were retrospectively evaluated 
regarding their previous therapies, serum PSA levels, 
PSA doubling times and PSA velocity. A serum PSA 
level of 0.83 ng/mL and a PSA doubling time of 6.5 
months were found to be valuable cut-off values for 
predicting with high probability a positive or negative 
scan result. In particular, 85% of patients with short 
PSA doubling times who were candidates for radio-
therapy to the prostate bed (early phase of biochemi-
cal recurrence with low PSA levels) showed positive 
findings on PET/CT, while only 18.7% of patients 
with similar low PSA levels, but with long PSA dou-
bling time were PET-positive. These preliminary re-
sults may contribute to a better selection of patients 
who potentially apply for PSMA PET/CT.  
The clinical studies so far convincingly demon-
strate that 68Ga-HBED-CC-PSMA is a promising tracer 
for detection of (metastatic) PCa cancer lesions, even 
in patients with relatively low PSA levels, which 
could lead to substantial improvements in clinical 
care, since tumor lesions can be detected in early 
stages of the disease (recurrence). However, the expe-
rience with 68Ga-HBED-CC-PSMA-PET/CT in clinical 
practice is still limited and several pitfalls have be-
come apparent. Krohn et al. reported the seemingly 
pathological uptake of 68Ga-HBED-CC-PSMA in coe-
liac ganglia [61]. In 76 of the 85 patients (89.4 %) at 
least one ganglion was observed. One should be 
aware of the uptake in coeliac ganglia when inter-
preting the images, although uptake in these ganglia 
was lower than in most tumor lesion: The average 
68Ga-HBED-CC-PSMA maximum lesion to mean 
background uptake ratio of lymph node metastases 
was 23.3 (range 5.3–115.8), whereas the average ratio 
for ganglia was 8.0 (range 2.8–30.6). 
PET/CT imaging with F-18-labeled PSMA lig-
ands 
Several groups have focused on the develop-
ment of 18F-labeled PSMA ligands for imaging of PCa. 
An advantage of the use of 18F as a radionuclide is the 
fact that it allows centralized production and com-
mercial distribution in greater areas and eliminates 
the need for on-site radiolabeling. In addition, multi-
ple doses of 18F can be produced in one synthesis, 
while no more than 2 doses of 68Ga can be synthezied 
at once. Moreover, imaging with 18F may result in 
higher image resolution and thus improved detection 
of tumor lesions. 
One of the first 18F-labeled PSMA ligands clini-
cally tested was developed by the group of Martin 
Pomper, who was one of the pioneers in the devel-
opment of 18F-labeled PSMA agents [45]. In this study, 
five patients with PCa and radiologic evidence for 
metastatic disease (median PSA 10.5 ng/mL, range 9.4 
– 46.5 ng/mL) were investigated using N-[N- 
[(S)-1,3-dicarboxypropyl] carbamoyl]-4-[18F]fluoro-
benzyl-L-cysteine ([18F]-DCFBC), a pentanedioic acid 
based compound. [18F]-DCFBC is structurally closely 
related to MIP-1072/1095, but labeled with 18F instead 
of 99mTc. Patients were investigated with both con-
ventional imaging modalities (CIM) such as bone 
scintigraphy, CT, ultrasound, or MRI, and with 
PET/CT using [18F]-DCFBC. Patients received 370 
MBq of [18F]-DCFBC, causing an estimated effective 
dose of 0.0199 mSv/MBq. The organs which absorbed 
the highest dose were the urinary bladder wall (0.0324 
mGy/MBq), stomach (0.0302 mGy/MBq), heart wall 
(0.0292 mGy/MBq) and kidneys (0.0284 mGy/MBq). 
Serial PET scans were performed until 2 h p.i. A total 
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of 42 lesions were visualized with either CIM or 
PET/CT. Twenty-one of the 32 lesions seen with 
PET/CT were concordant with the conventional im-
aging methods. Nearly all PET-positive lesions that 
were not visualized with CIM were located in the 
skeleton, suggesting superiority of PET/CT in the 
detection of early bone metastases. Most of the 
CIM-positive but PET-negative lesions were clinically 
interpreted as remodeling changes or benign frac-
tures. Based on these observations, the authors con-
cluded that [18F]-DCFBC-PET/CT is feasible for de-
tection of metastatic PCa lesions [45]. In a subsequent 
study, Rowe et al. evaluated the role of 
[18F]-DCFBC-PET/CT for detection and characteriza-
tion of primary PCa [62]. In this study, MR imaging 
demonstrated greater sensitivity for the detection of 
PCa whereas 18F-DCFBC-PET can potentially allow 
for more specific localization of the highest grade and 
most clinically significant tumor lesions than MR 
imaging. 18F-DCFBC-PET was, however, limited for 
detection of smaller-sized (<1.1 mL) and lower-grade 
(Gleason 7 or 6) tumors. The value of 
[18F]-DCFBC-PET/CT may lie in the fact that rela-
tively low 18F-DCFBC-PET uptake was observed in 
benign prostatic hypertrophy lesions, compared with 
cancer in the prostate, which may allow for more 
specific detection of primary PCa by 
18F-DCFBC-PET/CT [62]. 
Major disadvantage of [18F]-DCFBC is the con-
siderable blood pool activity. This is most likely 
caused by binding of the tracer to plasma proteins, 
which results in slow clearance, low tumor-to-blood 
ratios, and potentially interferes with the detection of 
lower avidity or smaller tumor lesions [62]. To ad-
dress this potential limitation, the group of Martin 
Pomper developed a second-generation 18F-labeled 
PSMA ligand, 2-(3-(1-carboxy-5-[(6-[18F]fluoro- 
pyridine-3-carbonyl)-amino]-pentyl)-ureido)-penta-
nedioic acid ([18F]-DCFPyL) [63, 64]. It was shown that 
the affinity of [18F]-DCFPyL for PSMA (Ki=1.1±0.1 
nM) was more than five times higher than that of 
[18F]-DCFBC [64]. Preclinical imaging using 
[18F]-DCFPyL demonstrated PSMA-expressing to 
PSMA-negative tumor ratios exceeding 300:1 at 2 h 
post-injection with minimal non-target tissue uptake 
[64]. Tumor uptake was 8-fold higher using 
[18F]-DCFPyL compared to [18F]-DCFBC. 
In a first-in-man evaluation in 9 patients with 
PCa, it was shown that [18F]-DCFPyL is safe to ad-
minister and that the biodistribution pattern parallels 
the known tissue distribution of PSMA. Compared to 
[18F]-DCFBC, the tumor-to-blood ratios seen with 
[18F]-DCFPyL were notably higher. In addition, rapid 
plasma clearance and low accumulation in the liver 
and muscle as compared to tumors lead to high tu-
mor-to-background ratios, resulting in a SUVmax 
greater than 100 in some lesions, which the authors 
attribute to internalization of the compound. Howev-
er, so far, no direct comparison between the internal-
ization rates of [18F]-DCFPyL and [18F]-DCFBC has 
been described. In addition to tumor uptake, the tu-
mor-to-blood ratios with [18F]-DCFPyL were notably 
higher than those of [18F]-DCFBC [63]. These findings 
indicate superiority of [18F]-DCFPyL- to 
[18F]-DCFBC-PET/CT in the detection of PCa lesions. 
The limitation of high blood pool activity of 
[18F]-DCFBC has been overcome by the use of 
[18F]-DCFPyL. 
Taken together, among the clinically tested 
PSMA inhibitors for PET imaging, 
68Ga-HBED-CC-PSMA and [18F]-DCFPyL seem to be 
the most suitable tracers so far, as they are safe and 
provide high tumor uptake as well as high tu-
mor-to-background ratios allowing high lesion detec-
tion rates. A direct comparison between both agents 
was recently described by Dietlein et al. [65]. In this 
study, 14 patients underwent both 
68Ga-HBED-CC-PSMA-PET/CT at 1 h p.i. and 
[18F]-DCFPyL-PET/CT at 2 h p.i.. It was shown that all 
lesions identified with 68Ga-HBED-CC-PSMA- 
PET/CT were detected with [18F]-DCFPyL-PET/CT. 
Most importantly, additional suspicious PCa lesions 
were detected in 3/14 patients with [18F]-DCFPyL, 
suggesting a higher sensitivity of [18F]-DCFPyL- 
PET/CT. In addition, significantly higher SUVmax 
values and higher tumor-to-background ratios were 
obtained with [18F]-DCFPyL than with 
68Ga-HBED-CC-PSMA. The authors hypothesize that 
the higher detection rate of [18F]-DCFPyL-PET/CT 
was at least partly due to the fact that [18F]-DCFPyL 
allowed later acquisition times, potentially leading to 
images with better signal-to-noise ratios. In addition, 
the faster clearance of [18F]-DCFPyL from the back-
ground might have contributed to the improved de-
tection rate. Overall, this study suggests that 
[18F]-DCFPyL may be a superior alternative to 
68Ga-HBED-CC-PSMA for imaging of recurrent PCa. 
However, further studies in larger patient cohorts are 
required to confirm these findings. 
While, so far, a considerable amount of attention 
was focused on the role of serum PSA levels on PSMA 
imaging, the role of androgen-deprivation therapy on 
PSMA imaging has not been evaluated clinically and 
remains unclear. Therefore, in future, clinical studies 
are needed that carefully characterize the influence of 
androgen-deprivation therapy on PSMA expression 
and the visualization of PSMA-expressing tumor le-
sions with PSMA-PET/CT. 
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PSMA Ligand-Based Radionuclide 
Therapy of Prostate Cancer 
Besides diagnostic imaging, radiolabeled PSMA 
ligands also have potential for radionuclide therapy of 
PCa. Zechmann et al. treated 28 patients with meta-
static castrate-resistant PCa with a single therapeutic 
dose of 131I-MIP-1095 (mean activity: 4.8 GBq, range 2 
– 7.2 GBq) [46]. In this study, the estimated radiation 
doses were compared with those reported for the 
177Lu-labeled anti-PSMA antibody J591. This compar-
ison revealed that the effective doses to the tumor 
obtained with 131I-MIP-1095 were markedly higher 
than those obtained with 177Lu-J591, while red mar-
row and kidney doses were similar when using 
131I-MIP-1095 [66], which showed the potential of 
these radiolabeled PSMA ligands for radionuclide 
therapy. PSMA uptake in healthy human tissue, such 
as the kidneys, salivary glands and the lower intes-
tines renders these tissues prone to toxic side effects 
[22, 52, 67]. No impairment of kidney function was 
observed in the study by Zechmann et al., as the glo-
merular filtration rate and creatinine levels remained 
normal within one year after treatment. The main 
observed side effects were a result of high salivary 
gland uptake; seven patients reported a dry mouth 
and in one patient, mucositis was observed. These 
symptoms disappeared 3-4 weeks after the treatment. 
Hematological toxicity of these doses of 131I-MIP-1095 
was mild. In 14 patients white blood cell counts fell 
below the normal range after therapy (10 patients 
with grade 1, 3 with grade 2 and one with grade 3 
toxicity). However, five of these 14 patients had levels 
below normal prior to therapy (4 grade 1, one with 
grade 2). Erythrocytes counts fell below the normal 
range 21 patients with 17 patients having lower values 
prior to therapy. Eleven patients had a reduction in 
platelet counts below normal after therapy, among 
which one patient had a value below normal prior to 
therapy.  
Administration of therapeutic doses of 
131I-MIP-1095 demonstrated high levels of tumor up-
take and prolonged retention up to 17 days after ad-
ministration. Therapeutic efficacy was demonstrated 
by symptom relief and by a decrease in serum PSA 
levels. After a single dose of up to 7.2 GBq 
131I-MIP-1095, in 61 % of the patients, a decline in se-
rum PSA levels of ≥50 % was observed; seven patients 
(25 %) had more than a 75 % decline in PSA level, and 
10 (35.7 %) had a drop between 50 and 75 %. Only 2 
patients (7.1 %) had a decline between 25 % and 50 %, 
and 2 (7.1 %) between 0 and 25 %. In only four pa-
tients, an increase of PSA was observed. A decrease in 
PSA was associated with a decrease in number 
and/or intensity of the lesions visualized on the post 
therapeutic PET/CT scan with 68Ga-PMSA-HBED- 
CC. The median time to PSA progression was 126 
days. Longer lasting responses may be obtained when 
consecutive doses of 131I-MIP-1095 will be adminis-
tered. Zechmann et al. showed that a therapeutic dose 
of 131I-MIP-1095 could be safely administered to pa-
tients with metastatic PCa, while keeping the radia-
tion dose to the healthy tissues at an acceptable level.  
 The tissue penetration range of β-particles of 
177Lu for radionuclide therapy is comparable to that of 
131I. However, one advantage of the use of 177Lu might 
be the fact that 177Lu is easier to distribute to centers 
where therapy with this radionuclide is provided. In 
addition, 177Lu presents a lower proportion of 
γ-radiation, which could result in a reduced stay in 
the hospital and lower hematological toxicity com-
pared with 131I [68]. Benesová et al. developed the 
novel theranostic PSMA agent 177Lu-DKFZ-617, which 
is a DOTA-conjugated Glu-urea-Lys analogue for 
both 177Lu- and 68Ga-labeling [69]. Preclinically, 
DKFZ-617 showed high tumor-to-background con-
trasts as early as 1 h after injection. Specific uptake 
was observed in PSMA-expressing tumors and in the 
kidneys. With regard to therapeutic use, the com-
pound exhibited a rapid clearance from the kidneys 
from 113.3 ± 24.4 at 1 h to 2.1 ± 1.4 % ID/g at 24 h. 
High tumor-to-muscle ratios at 24 h p.i. were report-
ed. Overall, the fast kidney clearance encouraged 
transfer of this compound into the clinics. 
Kratochwil et al. evaluated the therapeutic po-
tential of 177Lu-DKFZ-617 in one patient with meta-
static PCa [70]. In DKFZ-617, the chelator is conju-
gated via a linker containing two aromatic rings 
which is considered to improve tumor accumulation 
and reduce kidney uptake. In this report, one patient 
was treated with a cumulative activity of 7.4 GBq of 
177Lu-DKFZ-617. In pre-therapeutic PSMA PET/CT, a 
tumor phenotype with high PSMA ligand uptake was 
observed. After therapy, restaging with PSMA 
PET/CT revealed a striking radiological response and 
a decrease in PSA level from 38.0 to 4.6 ng/ml [70]. A 
prospective multicenter study to further evaluate the 
clinical potential of 177Lu-DKFZ-617 is currently 
planned. 
Baum et al. evaluated the role of 177Lu-DKFZ-617 
radionuclide therapy in a greater group of patients 
with PCa (n=53) [71]. In this study, 34 out of 53 pa-
tients received multiple therapy cycles (range: 2–5). 
The mean injected activity of 177Lu-PSMA per cycle 
was 5.7 ± 0.8 GBq (median, 5.8 GBq). The authors re-
port a molecular treatment response (partial remis-
sion) in 11 patients and a morphological response in 6 
patients. Stable disease was noted in 5 and 13 patients, 
according to molecular and morphological response 
criteria, respectively, whereas disease progressed in 8 
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patients. In this study, all symptomatic patients re-
ported significant improvement in pain and quality of 
life after therapy. The treatment was very well toler-
ated by all patients; no acute or long-term side effects 
were reported and no significant alterations in any of 
the laboratory parameters were observed. In particu-
lar, no hematological toxicity and change in renal 
function was observed.  
However, as PSMA is specifically expressed in 
the renal tubules of the kidneys, there is a risk for re-
nal toxicity which might be dose-limiting. In mice, 
Kratochwil et al. evaluated the role of the blocking 
agent 2-(phosphonomethyl)pentanedioic acid 
(PMPA), a known inhibitor of folate hydrolase activ-
ity of PSMA, in an attempt to block PSMA expressed 
in the kidneys [72]. BALB/c nude mice with subcu-
taneous PSMA+ LNCaP xenografts received different 
doses of PMPA at 16 h after injections of 
125I-MIP-1095, so the tracer would have sufficient time 
for tumor uptake and internalization as well as for 
tracer clearance from the bloodstream and kidney 
calices. It was demonstrated, that kidney uptake could 
be lowered without significantly diminishing tumor 
uptake. However, clinical studies that evaluate the 
potential of PMPA in patients have not yet been per-
formed.  
Overall, promising preliminary clinical data en-
courage further studies to evaluate the potential of 
endoradiotherapy of PCa using PSMA ligands. The 
added value of this therapeutic regimen needs to be 
compared to conventional PCa therapies. 
Theranostics Using PSMA Ligands 
With several PSMA ligands currently being 
tested clinically for diagnostic and therapeutic pur-
poses, agents which allow both diagnosis and therapy 
of PCa are getting more and more desirable. One of 
these agents that allows labeling with both 68Ga and 
177Lu is DKFZ-617 (mentioned above). This compound 
can thus be used for diagnostic and therapeutic pur-
poses [70, 71]. However, it was shown previously that 
DOTA-coupled PSMA ligands show significantly 
lower tumor uptake than HBED-CC-chelated agents 
[55]. In a first attempt to improve the pharmacokinet-
ics of the DOTA-coupled PSMA ligands, the hydro-
philicity of the ligand was increased by substitution of 
DOTA by 1,4,7,10-tetraazacyclodocecane,1-(glutaric 
acid)-4,7,10-triacetic acid (DOTAGA), resulting in 
DOTAGA-FFK(Sub-KuE) which can be labeled with 
both 68Ga and 177Lu and thus potentially be used for 
diagnostic and therapeutic purposes [73]. It was 
shown that DOTAGA-conjugated ligand complexes 
showed a significantly increased affinity towards 
PSMA on PSMA-expressing LNCaP cells compared to 
the DOTA-conjugated PSMA ligands [73].  
In an initial study in patients with metastatic 
castration-resistant PCa, 177Lu-DOTAGA-FFK(Sub- 
KuE) caused a significant reduction in metastatic tu-
mor load in some patients. To further improve the 
PSMA-affinity by increasing the lipophilic interaction 
of the tracer with the PSMA enzyme, a peptidic linker 
unit was introduced by Weineisen and colleagues in a 
subsequent study providing DOTAGA-(I-y)fk(Sub- 
KuE), termed PSMA I&T (for Imaging and Therapy) 
[74]. Compared with 177Lu-DOTAGA-FFK(Sub-KuE), 
177Lu-PSMA I&T was shown to have higher internal-
ization capacity, which might improve tumor uptake 
[74]. In this study, one patient underwent 68Ga-PSMA 
I&T PET/CT imaging which revealed high uptake in 
a primary prostate lesion (SUVmax 65.1) and a 
perirectal lymph node (SUVmax 15.0). Another patient 
was treated with 200µg (8.0GBq) of 177Lu-PSMA I&T, 
which resulted in partial remission of many of the 
intense PSMA-positive metastatic lesions depicted by 
pre-therapeutic 68Ga-PSMA-HBED-CC PET/CT 
which was accompanied by a drop in SUVmax from 
26.3 to 3.0 in a paraaortic lymph node and a signifi-
cant drop in PSA serum level from 54.2 to 0.7 ng/ml 
[74]. In addition, symptomatic pain relief was re-
ported. Taken together, these results suggest high 
potential of 177Lu-PSMA I&T radionuclide therapy in 
the destruction of PCa lesions.  
Subsequently, Herrmann et al. have evaluated 
the biodistribution and radiation dosimetry of 
68Ga-PSMA I&T in 5 patients [75]. It was shown that 
68Ga-PSMA I&T exhibits promising dosimetry which 
compares favorably with other PCa specific probes 
such as 123I-MIP-1072 or -1095 [75]. 68Ga-PSMA I&T 
was tolerated by all patients without acute or sub-
acute adverse events and without significant changes 
in blood count, kidney or hepatic function. High le-
sion-to-background uptake ratios were observed as 
early as 30min after administration, however, the best 
contrast was achieved at 1h p.i.. 
 Taken together, these promising preliminary 
results suggest that PSMA I&T can be used for both 
diagnostic imaging as well as for radionuclide thera-
py. However, even though the potential theranostic 
uses of 68Ga-PSMA I&T are appealing, as far as we 
know, no direct comparison between 68Ga-PSMA 
I&T-PET/CT and 68Ga-HBED-CC-PSMA-PET/CT 
concerning diagnostic imaging of PCa has been per-
formed, yet. Therefore, before a theranostic com-
pound could replace the so far more frequently tested 
68Ga-HBED-CC-PSMA-PET/CT, diagnostic accuracy 
of both agents needs to be directly compared to each 
other.  
 In addition, other tracers which so far have 
mainly been used for therapeutic strategies might be 
used for diagnostic applications, too, such as the 
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DOTA-conjugated DKFZ-617 PSMA ligand. 
Surgical Guidance with PSMA Ligands 
Next to diagnostic applications and endoradio-
therapy, PSMA ligands can potentially be used for 
other therapeutic strategies such as image-guided 
surgery of PCa lesions. At present, radical prostatec-
tomy represents the gold standard in surgical treat-
ment of PCa. However, frequently, small amounts of 
tumor tissue as well as micrometastases cannot be 
visualized during surgery and are not resected, po-
tentially causing recurrence of the disease [76]. To 
avoid this, imaging techniques are needed that allow 
real-time intra-operative visualization and im-
age-guided resection of small amounts of residual 
tumor tissue.  
Potentially, PCa lesions can be detected in-
tra-operatively using radio-guided surgery. While 
imaging of even small and metastatic PCa lesions and 
lymph nodes is possible with PET/CT using 
68Ga/18F-labeled PSMA ligands, intraoperative detec-
tion of such lesions may not be easy owing to their 
inconspicuous morphology and atypical localization. 
To improve intra-operative lesion detection and allow 
radio-guided surgery, Maurer et al. developed ra-
dio-guided surgery for PCa using 111In-labeled PSMA 
ligands [77]. Because of its favorable half-life of 2.8 d, 
initially PSMA-HBED-CC was labeled with 111In. 
However, due to instability of this complex, 
111In-PSMA I&T was used for radio-guided surgery 
instead. Five patients underwent 
68Ga-PSMA-HBED-CC-PET/CT followed by surgery 
with intra-operative detection of tumor lesions using 
a gamma probe at 24h after injection of 146MBq 
(110-169MBq) of 111In-PSMA I&T. All PET-positive 
lesions were detected by PSMA-radio-guided surgery. 
Histologic analyses confirmed that all resected tissue 
specimens exhibiting positive measurements in vivo 
and ex vivo were PSMA positive. Moreover, addi-
tional tumor lesions of 2-4mm size close to known 
tumor deposits were identified in 2 of 5 patients. 
Overall, this study shows that radio-guided surgery 
can lead to improvements in the resection of PCa.  
Another approach to detect tumor lesions in-
tra-operatively for image-guided resection is by using 
in vivo fluorescence imaging. Neuman et al. evaluated 
the role of the low-molecular weight urea-based flu-
orescent agent YC-27, 2-(3-{5-[7-(5-amino-1-carboxy- 
pentylcarbamoyl)-heptanoylamino]-1-carboxy- 
pentyl}-ureido) pentanedioic acid conjugated to the 
near-infrared fluorescent dye IRDye800CW [78] for 
real-time near-infrared fluorescence imaging of sur-
gical margins and image-guided resection of remain-
ing PCa lesions in a mouse model of PCa [76]. In this 
study, nu/nu mice with subcutaneous 
PSMA-expressing tumors received intravenous injec-
tions of 19.1 µg/kg of YC-27 and underwent im-
age-guided surgery with a fluorescence imaging sys-
tem. Within 30 days after surgery, none of the animals 
resected with image-guidance developed a recur-
rence, while 40% of the animals with tumors resected 
by conventional surgery had recurrent disease within 
that period of time. These data indicate that a 
near-infrared fluorophore targeted to PSMA allows 
improvements in surgical treatment of PCa by reduc-
tion of positive surgical margins. One potential ad-
vantage above radio-guided surgery might be the fact 
that the fluorescence system allows real-time visuali-
zation of tumor tissue instead of localization based on 
acoustic signals as it is the case for radio-guided 
strategies. However, the use of fluorescence is re-
stricted by the relatively low tissue penetration depth 
of 1-2 cm of emitted near-infrared light. To overcome 
the limitations of both radio-guidance and fluorescent 
approaches, a dual-labeling approach in which PSMA 
ligands are conjugated to both a fluorescent label as 
well as a radionuclide would be needed, which allows 
both visual and acoustic tumor detection.  
Conclusion and Future Perspectives 
Diagnosis, (re)staging, and therapy of PCa entail 
different challenges in the management of patients 
with PCa, which still pose major challenges to today`s 
medical care. PSMA ligands show great potential for 
initial staging, lymph node staging, and restaging of 
PCa. With PSMA ligands, limitations of choline-based 
imaging, such as the relatively low sensitivity, espe-
cially in patients with low PSA levels and Gleason 
scores, can be overcome. In addition, first clinical 
studies show the potential of PSMA ligands for ther-
apeutic strategies such as targeted radiation delivery 
or image-guided surgery. At present, 99mTc-MIP-1404 
seems to be the most promising tracer for SPECT im-
aging of PCa, while 68Ga-labeled HBED-CC-PSMA 
and 18F-labeled DCFPyl represent the most promising 
tracers for PET imaging of patients with PCa. Further 
studies that directly compare both agents under iden-
tical conditions are needed, to identify which agent is 
superior. Unfortunately, so far, both 68Ga-HBED-CC- 
PSMA and 18F-DCFPyl are restricted to diagnostic 
purposes. An interesting variant that potentially 
combines both diagnosis and therapy of PCa are the 
compounds DKFZ-617 and PSMA I&T as they can be 
labeled with 68Ga for diagnostic purposes as well as 
with 177Lu for therapeutic approaches. In future, more 
research on imaging and therapy of PCa with PSMA 
ligands in patient cohorts exhibiting low PSA levels in 
particular is needed to determine up to which PSA 
levels imaging with PSMA ligands can uphold its 
high sensitivity. Moreover, PSMA imaging studies 
 Theranostics 2015, Vol. 5, Issue 12 
 
http://www.thno.org 
1400 
need to be performed in PCa patients that have re-
cently received or are under androgen deprivation 
therapy to investigate the role of PSMA imaging in 
this patient population. In addition, the potential of 
PSMA ligand-based imaging and therapy of 
soft-tissue and bone metastases should be evaluated.  
 Another interesting application of PCa would be 
intra-operative detection and radio/image-guided 
resection of tumor lesions within the prostate as well 
as of tumor-containing lymph nodes. For this pur-
pose, dual-labeling strategies using fluorescent and 
radionuclide imaging are desirable, which allow 
pre-operative visualization of PCa lesions by radio-
nuclide imaging techniques as well as intra-operative 
acoustic and visual localization of PSMA-expressing 
tumor lesions, permitting signal-guided resection of 
tumors. 
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